PDCD1 and neoplasm: Tumor mutational burden (TMB) high (≥10 mutations/Megabase (Muts/Mb)) and microsatellite instability high (MSI-H) are biomarkers for which pembrolizumab (17), an anti-PD-1 agent, is approved in the tumor-agnostic setting (18, 19).